Increased pre beta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes

Human plasma phospholipid transfer protein (PLTP) circulates' bound to high density lipoprotein (HDL) and mediates both net transfer and exchange of phospholipids between different lipoproteins. However, its overall function in lipoprotein metabolisin is unknown, To assess the effects of increased plasma levels of PLTP, human PLTP transgenic mice were established using the human PLTP gene driven by its natural promoter, One line of PLTP transgenic mice with moderate expression of PLTP mRNA and protein was obtained, The order of human PLTP mRNA expression in tissues was: liver, kidney, brain, small intestine > lung > spleen > heart, adipose tissue, Western blotting using a human PLTP monoclonal antibody revealed authentic human PLTP (M(r) 80 kD) in plasma. Plasma PLTP activity was increased by 29% in PLTP transgenic mice, However, plasma lipoprotein analysis, comparing PLTP transgenic mice to control littermates, revealed no significant changes in the plasma lipoprotein lipids or apolipoproteins, Since previous studies have shown that human cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase only function optimally in human apoAI transgenic mice, the human PLTP transgenic mice were cross-bred with human apoAI transgenic mice, In the human apoAI transgenic background, PLTP expression resulted in increased PLTP activity (47%), HDL phospholipid (26%), cholesteryl ester (24%), free cholesterol (37%), and apoAI (22%), There was a major increase of apoAI in pre beta-HDL (56%) and a small increase in alpha-HDL (14%). The size distribution of HDL particles within alpha- and pre beta-migrating species was not changed. The results suggest that PLTP increases the influx of phospholipid and secondarily cholesterol into HDL, leading to an increase in potentially antiatherogenic pre beta-HDL particles.